André Francis, Van Damme Pierre, Safary Assad, Banatvala Jangu
GlaxoSmithKline Biologicals, Rixensart, Belgium.
Expert Rev Vaccines. 2002 Jun;1(1):9-23. doi: 10.1586/14760584.1.1.9.
There is 10 years of marketing experience with the hepatitis A vaccine Havrix. It is highly immunogenic, provides lasting protection in healthy individuals and generates protective levels of antibodies in patients with chronic liver disease or impaired immunity. Postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. The timing of the booster dose is not critical to effectiveness, which has advantages for the protection of travelers to regions of high endemicity. The vaccine is effective in curbing outbreaks of hepatitis A and also when administered postexposure, due to rapid seroconversion and the long incubation period of the disease. In intermediate endemic regions, an epidemiological shift in hepatitis A infection has driven the development of universal preventive strategies to be added to the targeting of at-risk groups. Existing official recommendations and future directions for vaccine use are reviewed.
甲型肝炎疫苗贺福立适有10年的市场推广经验。它具有高度免疫原性，能为健康个体提供持久保护，并在慢性肝病或免疫功能受损的患者中产生保护性抗体水平。上市后监测数据证实了该疫苗出色的安全性。加强剂量的接种时间对有效性而言并不关键，这对保护前往高流行地区的旅行者具有优势。该疫苗在遏制甲型肝炎疫情方面有效，并且在暴露后接种时也有效，这是由于其血清转化迅速且疾病潜伏期长。在中等流行地区，甲型肝炎感染的流行病学转变推动了通用预防策略的发展，以补充针对高危人群的策略。本文对现有的官方建议和疫苗使用的未来方向进行了综述。
